Related references
Note: Only part of the references are listed.Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
Kuo-Hsing Chen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Nathalie Gaspar et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
Andy Yingjie Lin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group
Patrick J. Leavey et al.
PEDIATRIC BLOOD & CANCER (2008)
Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma
B. I. Ferreira et al.
ONCOGENE (2008)
Survival after recurrence of Ewing's sarcoma family of tumors
LM Barker et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High frequency of genomic instability in Ewing family of tumors
A Ohali et al.
CANCER GENETICS AND CYTOGENETICS (2004)
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997
G Bacci et al.
ANNALS OF ONCOLOGY (2003)
Survival after recurrence of Ewing tumors - The St. Jude Children's Research Hospital experience, 1979-1999
C Rodriguez-Galindo et al.
CANCER (2002)
Share Paper
